A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study

Background: Radiotherapy is one of the most frequently selected treatment options for patients with prostate cancer. However, adverse effects related to the irradiated surrounding normal organs are significant clinical concerns. Specifically, genitourinary and gastrointestinal toxicities can lead to...

Full description

Bibliographic Details
Main Authors: Makito Miyake, Nobumichi Tanaka, Isao Asakawa, Kaori Yamaki, Takashi Inoue, Shota Suzuki, Shunta Hori, Yasushi Nakai, Satoshi Anai, Kazumasa Torimoto, Michihiro Toritsuka, Hitoshi Nakagawa, Shinji Tsukamoto, Tomomi Fujii, Chiho Ohbayashi, Masatoshi Hasegawa, Masato Kasahara, Kiyohide Fujimoto
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Contemporary Clinical Trials Communications
Subjects:
Prostate cancer
Urinary frequency
Low-dose-rate brachytherapy
Radiotherapy
Radioprotection
5-Aminolevulinic acid
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865420300776

Internet

http://www.sciencedirect.com/science/article/pii/S2451865420300776

Similar Items